Controlling β-Sheet Assembly in Genetically Engineered Silk by Enzymatic Phosphorylation/Dephosphorylation†

Biochemistry ◽  
2000 ◽  
Vol 39 (41) ◽  
pp. 12739-12746 ◽  
Author(s):  
S. Winkler ◽  
D. Wilson ◽  
D. L. Kaplan
Keyword(s):  
Genetically Engineered ◽  
Enzymatic Phosphorylation ◽  
Β Sheet

scholarly journals Controlling β-Sheet Assembly in Genetically Engineered Silk by Enzymatic Phosphorylation/Dephosphorylation, by

Biochemistry ◽  
2000 ◽  
Vol 39 (45) ◽  
pp. 14002-14002 ◽  
Author(s):  
S. Winkler ◽  
D. Wilson ◽  
D. L. Kaplan
Keyword(s):  
Genetically Engineered ◽  
Enzymatic Phosphorylation ◽  
Β Sheet

scholarly journals Inhibition of peptide aggregation by means of enzymatic phosphorylation

2016 ◽  
Vol 12 ◽  
pp. 2462-2470 ◽  
Author(s):  
Kristin Folmert ◽  
Malgorzata Broncel ◽  
Hans v. Berlepsch ◽  
Christopher Hans Ullrich ◽  
Mary-Ann Siegert ◽  
...  
Keyword(s):  
Amyloid Fibrils ◽  
Conformational Transition ◽  
Structural Characteristics ◽  
Random Coil ◽  
Amyloid Formation ◽  
Initial Growth ◽  
Amyloid Fibril Formation ◽  
Dependent Protein ◽  
Enzymatic Phosphorylation ◽  
Β Sheet

As is the case in numerous natural processes, enzymatic phosphorylation can be used in the laboratory to influence the conformational populations of proteins. In nature, this information is used for signal transduction or energy transfer, but has also been shown to play an important role in many diseases like tauopathies or diabetes. With the goal of determining the effect of phosphorylation on amyloid fibril formation, we designed a model peptide which combines structural characteristics of α-helical coiled-coils and β-sheets in one sequence. This peptide undergoes a conformational transition from soluble structures into insoluble amyloid fibrils over time and under physiological conditions and contains a recognition motif for PKA (cAMP-dependent protein kinase) that enables enzymatic phosphorylation. We have analyzed the pathway of amyloid formation and the influence of enzymatic phosphorylation on the different states along the conformational transition from random-coil to β-sheet-rich oligomers to protofilaments and on to insoluble amyloid fibrils, and we found a remarkable directing effect from β-sheet-rich structures to unfolded structures in the initial growth phase, in which small oligomers and protofilaments prevail if the peptide is phosphorylated.

Reduction−Oxidation Control of β-Sheet Assembly in Genetically Engineered Silk

2000 ◽  
Vol 1 (4) ◽  
pp. 534-542 ◽  
Author(s):  
Sandra Szela ◽  
Peter Avtges ◽  
Regina Valluzzi ◽  
Stefan Winkler ◽  
Donna Wilson ◽  
...  
Keyword(s):  
Genetically Engineered ◽  
Β Sheet

scholarly journals Reversible Thermal Denaturation of a 60-kDa Genetically Engineered β-Sheet Polypeptide

2006 ◽  
Vol 91 (10) ◽  
pp. 3805-3818 ◽  
Author(s):  
Igor K. Lednev ◽  
Vladimir V. Ermolenkov ◽  
Seiichiro Higashiya ◽  
Ludmila A. Popova ◽  
Natalya I. Topilina ◽  
...  
Keyword(s):  
Thermal Denaturation ◽  
Genetically Engineered ◽  
Β Sheet

Reproductive health issues in patients with psoriasis (literature review)

2019 ◽  
Vol 1 (7) ◽  
pp. 5-8
Author(s):  
L. S. Kruglova ◽  
A. A. Osina ◽  
A. A. Khotko
Keyword(s):  
Drug Therapy ◽  
Reproductive Health ◽  
Literature Review ◽  
Pregnancy Outcomes ◽  
Adverse Pregnancy Outcome ◽  
Certolizumab Pegol ◽  
Genetically Engineered ◽  
Health Issues ◽  
Degree Of Confidence ◽  
Adverse Pregnancy

Among patients with psoriasis, approximately 50% are women and almost 75 % of them are under the age of 40 years. Thus, most women with psoriasis have childbearing potential. When pregnancy occurs in 22 % of patients, the activity of psoriasis persists, characteristic of the course before pregnancy, in 23 % of women, the course of the disease worsens. The article provides up-to-date data on the management of pregnant patients with psoriasis. To improve pregnancy outcomes in patients with psoriasis, it is important to prevent exacerbation of the disease. The choice of drug therapy in this case is based on an assessment of the ratio of the risk of undesirable effects of the drugs on the developing fetus and the risk of the development of exacerbation of psoriasis, which can cause an adverse pregnancy outcome. Despite the fact that the available clinical experience of using genetically engineered drugs is still limited, with a certain degree of confidence we can say that there is no increase in the risk of adverse pregnancy outcomes associated with therapy with certolizumab pegol.

Quantum Dot Bioconjugates as Energy Donors in Fluorescence Resonance Energy Transfer Assays

2003 ◽  
Vol 773 ◽  
Author(s):  
Aaron R. Clapp ◽  
Igor L. Medintz ◽  
J. Matthew Mauro ◽  
Hedi Mattoussi
Keyword(s):  
Energy Transfer ◽  
Quantum Dot ◽  
Organic Dyes ◽  
Resonance Energy Transfer ◽  
Resonance Energy ◽  
Genetically Engineered ◽  
Molar Ratio ◽  
Binding Assays ◽  
Specific Sequence ◽  
Donor Acceptor

AbstractLuminescent CdSe-ZnS core-shell quantum dot (QD) bioconjugates were used as energy donors in fluorescent resonance energy transfer (FRET) binding assays. The QDs were coated with saturating amounts of genetically engineered maltose binding protein (MBP) using a noncovalent immobilization process, and Cy3 organic dyes covalently attached at a specific sequence to MBP were used as energy acceptor molecules. Energy transfer efficiency was measured as a function of the MBP-Cy3/QD molar ratio for two different donor fluorescence emissions (different QD core sizes). Apparent donor-acceptor distances were determined from these FRET studies, and the measured distances are consistent with QD-protein conjugate dimensions previously determined from structural studies.

Sign in / Sign up

Export Citation Format

Share Document